|
Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality?
|
May 2020
|
Best practice & research. Clinical haematology
|
myelodysplastic syndromes (MDS)
|
|
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM)
|
Apr 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of
|
Apr 2020
|
Bone Marrow Transplantation
|
aplastic anemia
|
|
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
|
Apr 2020
|
Blood Advances
|
aplastic anemia
|
|
Rewriting the rules for care of MDS and AML patients in the time of COVID-19
|
Apr 2020
|
Leukemia Research Reports
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Alcohol use is not a significant contributor to myelodysplastic syndromes
|
Apr 2020
|
Cancer Causes & Control : CCC
|
myelodysplastic syndromes (MDS)
|
|
Targeting TP53 Mutations in Myelodysplastic Syndromes
|
Apr 2020
|
Hematology/oncology clinics of North America
|
myelodysplastic syndromes (MDS)
|
|
Evolving therapies for lower-risk myelodysplastic syndromes
|
Apr 2020
|
Annals of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities
|
Mar 2020
|
Clinical Lymphoma , Myeloma & Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
|
Mar 2020
|
Expert Review of Hematology
|
myelodysplastic syndromes (MDS)
|
